Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Intracochlear Dexamethasone

PreclinicalSmall molecule

PPamukkale University

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hearing Loss, SensorineuralRecruiting

Hearing Loss, SensorineuralPreclinical

Recruiting

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Hearing Loss, Sensorineural

NCT05215197

Clinical

Trials by Indication[1]

Dexamethasone1 trial

Intracochlear Dexamethasone Application During Cochlear Implantation for Preserving Cochlear Cells

Completed·PPamukkale University·N/A·NCT04397354·34 enrolled

Hearing Loss, Sensorineural1 trial

Intracochlear Platelet-rich Fibrin Application in Cochlear Implantation

Recruiting·PPamukkale University·Preclinical·NCT05215197·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Intracochlear Dexamethasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intracochlear Dexamethasone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intracochlear Dexamethasone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pamukkale University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPamukkale University

Related News